Dawn Lombardo, DO
Advanced Heart Failure and Transplant Cardiology · Orange, CANPI 1205944485
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Masimo Corporation at 30.8% of the total. Reporting peaked in 2023 at $6,977 and has fallen 56.8% since, to $3,013 in 2025.
Across 57 payments — averaging $239.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Masimo Corporation$4K
- Abbott$3K
- Abiomed$3K
- Edwards Lifesciences$2K
- Novartis$280
- Agepha Pharma FZ LLC$274
- plus $702 from 6 others
Across 415 payments — averaging $2865.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$326K
- Boehringer Ingelheim International GmbH$301K
- Applied Therapeutics, Inc.$160K
- Boehringer Ingelheim$92K
- AstraZeneca$81K
- Merck$67K
- plus $162K from 5 others
What the payments were for
- Consulting fees$6,47547%
- Travel & lodging$3,96629%
- Food & beverage$3,08723%
- Education$1461%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Masimo Corporation | 4 | $4,217 |
| Abbott | 28 | $3,150 |
| Abiomed | 10 | $2,776 |
| Edwards Lifesciences | 1 | $2,275 |
| Novartis | 4 | $280 |
| Agepha Pharma FZ LLC | 1 | $274 |
| Shockwave Medical, Inc | 1 | $168 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $146 |
| Ancora Heart, Inc. | 1 | $132 |
| Cvrx, Inc. | 1 | $122 |
| Boston Scientific | 3 | $82 |
| Biotronik Inc. | 1 | $52 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Patient SafetyNet System$3,413
- Impella$2,452
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,389
- EMMA and ISA$438
- Bridge$350
- LODOCO$274
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$168
- AccuCinch$132
- HeartMate 3 Left Ventricular Assist Device$126
- Barostim Neo System$122
- ENTRESTO$114
- LEQVIO$114
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$112
How this compares
$13,674 in reported general payments places this provider in the 55th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 11 | $21,156 |
| EliquisApixaban | 13 | $13,751 |
| Metoprolol Succinate | 26 | $655 |
| Ezetimibe | 11 | $291 |
| Atorvastatin Calcium | 16 | $285 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $280 | $21,15611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in Orange
- Behram ModyOrange$17K
- Richard WrightSanta Monica$1.7M
- James Heywoodla Jolla$1.2M
- Hirsch MehtaSan Diego$494K
- Teresa de MarcoSan Francisco$366K
- Rajeev Mohanla Jolla$357K
- Marcus UreySan Diego$341K
- Munir JanmohamedSacramento$314K
- Barry GreenbergSan Diego$270K
- Ronald WittelesStanford$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.